Change description : 2025-07-14 14:00:00: Updated to include nirsevimab selective immunisation programme information. Updates to older adult adverse reactions section, older adult coadministration, and on recent efficacy and disease burden evidence. [Guidance and regulation]
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
Respiratory syncytial virus (RSV) is an enveloped RNA virus that belongs to the Paramyxoviridae family within the Pneumovirus genus. The virus has a non-segmented, single stranded, negative sense genome that encodes 11 proteins.
RSV is a common cause of respiratory tract infections. It causes a mild self-limiting respiratory infection in adults and children, but it can be severe in infants and older adults who are at increased risk of acute lower respiratory tract infection.
Added minor revision to older adult adverse reactions section.
6 February 2025
Updated with recent evidence on vaccine safety and effectiveness, and latest JCVI advice on selective immunisation with monoclonal antibodies.
1 October 2024
Links to national immunisation programme letters added, revised in alignment with the 4 national programmes.
22 July 2024
Updated with detail of vaccine supply for Wales.
12 July 2024
Updated to include the new RSV maternal and older adults immunisation programme.
4 September 2015
The chapter has been updated to provide clearer definitions of the groups in whom palivizumab use is advised. Revisions to the chapter also take into account the revised formulation of Synagis® as a solution for injection.